Hyperprolactinemia, Sexual Dysfunction
Conditions
Keywords
schizophrenia, risperidone, paliperidone, aripiprazole
Brief summary
This trial designed to investigate the effect of switching to aripiprazole from risperidone or paliperidone on reverse prolactin level, and consequently improve sexual dysfunction in adult patients with schizophrenia spectrum disorders and bipolar spectrum disorders.
Interventions
DRUGAripiprazole
Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
DRUGrisperidone or paliperidone
Sponsors
Si Tianmei
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
1. Age: 12-55 years (male), 12-40 (female) 2. Diagnosis: Schizophrenia spectrum disorders & bipolar spectrum disorders (only Korea) by DSM-IV-TR 3. Receiving RIS or PALI with stable dose for \> 1 month by their physician; 4. Prolactin level Adult: \> 20 ng/ml (male), 25 ng/ml (female) Child/Adolescent: \> 20 ng/ml (male, female) 5. Children and adolescents (age: 12\ 17 years) having more than one sexual system dysfunction measured by 5 of the 48 UKU items (galactorrhoea, gynecomastia and erectile dysfunction for male, galactorrhea, amenorrhoea/oligomenorrhoea, and dry vagina for female) or Adults (age: 18\ 55 years) who are considered to have sexual/reproductive dysfunction if they had either a total score of 19 or higher; a score of 5 or higher on one question; or a score of 4 or higher on 3 questions. 6. Subjects who have consented to participate by signing an informed consent form. \-
Exclusion criteria
1. Medical disorder or psychiatric comorbidity or condition known to affect prolactin, sex hormone balance or bone metabolism (i.e., unstable medical disease, Cushing's disease, chronic renal failure, thyroid dysfunction, eating disorder) 2. History of hematological and/or solid malignancies 3. Physical or functional obstruction to food intake or impaired digestive/absorptive function 4. Known hypersensitivity to any study medication (risperidone, paliperidone, and aripiprazole) 5. Insulin requiring diabetes mellitus or poorly controlled diabetes mellitus (HbA1c \> 9% or change of antidiabetics treatment within the 12weeks prior to screening) 6. Uncontrolled hypertension (SBP/DBP 140/90 mmHg), congestive heart failure (NYHA class III or IV), other significant cardiovascular illness (myocardial infarction, unstable angina, cardiac arrhythmia etc.) 7. Baseline QTc interval of \> 450 msec 8. Hepatic and/or renal dysfunction 1\) Bilirubin level ≥ 1.5 upper normal limits 2) AST/ALT ≥ 3 UNL or 3) Serum creatinine ≥ 1.5 9. Any patient hospitalized for acute exacerbation of their condition within 2 months of randomization 10. Recent (within the past 1 month) or planned treatment with prohibited medications in the protocol \-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in severity of sexual/reproductive system dysfunction at 12 weeks | 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of absence of sexual/reproductive system dysfunction on the UKU side effect rating scale or ASEX | 12 weeks |
Countries
China
Contacts
Primary ContactTianmei Si, MD.
Outcome results
None listed